Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

janssen - cilag, s.a. de c.v. - clorhidrato de pramoxina - clorhidrato de pramoxina....1 g / acetato de zinc....0.1 g

Israel - English - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 3 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Israel - English - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 6 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

Israel - English - Ministry of Health

j-c health care ltd - paliperidone - tablets extended release - paliperidone 9 mg - paliperidone - paliperidone - invega is indicated for :-treatment of schizophrenia in adults and adolescents (12-17 years).-treatment of schizoaffective disorder in adults.

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 4 mg - other antipsychotic - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; in patients with moderate to severe alzheimer's dementia; forf persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 3 mg - other antipsychotic - it al is used to treat the following: schizophrenia, mania, aggression in people with alzheimer’s dementia, aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - abiraterone acetate, quantity: 500 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; silicified microcrystalline cellulose; hypromellose; magnesium stearate; silicon dioxide; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - zytiga is indicated in combination with prednisone or prednisolone for the treatment of: ? newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (adt), or ? patients with metastatic advanced prostate cancer (castration resistant prostate cancer, mcrpc) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (adt) or ? patients with mcrpc who have received prior chemotherapy containing a taxane.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.